in vitro News and Research

RSS

Cyclin D1 oncogene may promote chromosomal instability

A team of researchers at Jefferson's Kimmel Cancer Center (KCC) led by Richard G. Pestell, M.D., PhD., FACP, Director of the KCC and Chair of the Department of Cancer Biology, have shown in a study published online Feb. 6 in the Journal of Clinical Investigation that the oncogene cyclin D1 may promote a genetic breakdown known as chromosomal instability (CIN). CIN is a known, yet poorly understood culprit in tumor progression.

7 Feb 2012

ABC2, Exosome collaborate to explore RNA biofluid-based diagnostic technology in brain cancer

Accelerate Brain Cancer Cure and Exosome Diagnostics are collaborating with leading academic medical centers to accelerate clinical validation of Exosome's blood and cerebrospinal fluid-based molecular diagnostics technology in brain cancer.

6 Feb 2012

Longer looks: Enhanced scrutiny of IVF clinics; School-based health care

Republican presidential contender Newt Gingrich hit upon a reproductive minefield on Sunday when he called for deeper scrutiny of in vitro fertilization (IVF) clinics, where women go for high-tech help to conceive.

3 Feb 2012

Multiple DNA repair defect in monocytes

Scientists working with Professor Bernd Kaina of the Institute of Toxicology at the Medical Center of Johannes Gutenberg University Mainz have demonstrated for the first time that certain cells circulating in human blood - so-called monocytes - are extremely sensitive to reactive oxygen species (ROS).

3 Feb 2012

BU scientists create unique material and drug delivery mechanism

Long duration, controllable drug delivery is of wide interest to medical researchers and clinicians, particularly those seeking to improve treatment for patients with chronic pain or to prevent cancer recurrence after surgery. Now a team of researchers led by Boston University Biomedical Engineer and Chemist Mark Grinstaff has developed a unique material and drug delivery mechanism that could pave the way for implants that release a drug at a designated rate for months.

1 Feb 2012

NanoViricides files FluCide pre-IND briefing document with the FDA

NanoViricides, Inc. announced today that it has submitted a pre-IND briefing document to the US FDA. This submission provides the required information for the Company's highly effective anti-influenza drug candidate, FluCide, in support of a pre-IND Meeting.

1 Feb 2012

Nanosize titanates may inhibit growth of oral cancer and bacterial cell lines

Sometimes bigger isn't better. Researchers at the U.S. Department of Energy's Savannah River National Laboratory have successfully shown that they can replace useful little particles of monosodium titanate (MST) with even tinier nano-sized particles, making them even more useful for a variety of applications.

1 Feb 2012

Pannexin1 protein may play an important role in mechanics of tumors

By studying tumor cell behavior in a novel "scaffold-free" 3-D system, researchers have determined that the protein Pannexin1 may play an important biomechanical role in binding tissues together, an effect that is lost in cancerous cells.

31 Jan 2012

ASI's GenASIs for detection of chromosomal aberrations in bladder cancer receives FDA approval

Applied Spectral Imaging (ASI) announced today that ASI's GenASIs Scan & Analysis, SpotScan used for the detection of chromosomal aberrations in bladder cancer has been cleared by the United States Food and Drug Administration (FDA) for marketing in the US.

30 Jan 2012

Strong link between high HuR protein levels and malignancy of HCC

Researchers at CIC Biogune, the Cooperative Centre for Research into Biosciences and led by Dr. Maria Luz Martinez Chantar, have found a strong relationship between high levels of Hu antigen R (HuR) protein and the malignancy of Hepatocellular Carcinoma, through a novel molecular process in the investigation of this pathology and known as neddylation.

27 Jan 2012

Breakthroughs in Alzheimer’s disease research

Researchers are closer to understanding Alzheimer’s disease using a new stem cell technique. They have successfully replicated Alzheimer’s disease neurons with stem cells for the first time.

26 Jan 2012

Aphios receives NIH's Phase II SBIR grant to develop APH-0703 for AD

Aphios Corporation has received a Phase II SBIR grant from the National Institutes of Health (NIH) amounting to $2.4 million over two years. The National Institute on Aging (NIA), part of the NIH, awarded the grant to the Aphios Corporation to develop an "Alzheimer's Disease Therapeutic."

24 Jan 2012

CQA derivatives in mate tea kill human colon cancer cells

Could preventing colon cancer be as simple as developing a taste for yerba mate tea? In a recent University of Illinois study, scientists showed that human colon cancer cells die when they are exposed to the approximate number of bioactive compounds present in one cup of this brew, which has long been consumed in South America for its medicinal properties.

24 Jan 2012

NCI-funded project aims to shed new light on implications for bone metastasis in prostate cancer

Prostate cancer is the most frequent and second deadliest cancer men face. A team of Wayne State University researchers recently received $363,660 from the National Cancer Institute of the National Institutes of Health for the project - "Bone-induced c-kit in prostate cancer cells: implications for bone metastasis" - that aims to shed new light on implications for bone metastasis in prostate cancer.

21 Jan 2012

FDA allows marketing of Stratify JCV Antibody ELISA test for PML

Today, the U.S. Food and Drug Administration allowed marketing of the first test to help determine the risk for a rare brain infection called progressive multifocal leukoencephalopathy (PML) in people using the drug Tysabri (natalizumab) to treat multiple sclerosis (MS) or Crohn's disease.

21 Jan 2012

Biotectix announces FIH use of electrostimulation device with BT DOT polymer coatings

Biotectix, LLC, an Allied Minds, Inc. subsidiary, is pleased to announce the first-in-human (FIH) use of an electrostimulation device incorporating its BT DOT conductive polymer coating technology.

19 Jan 2012

RaNA Therapeutics completes $20.7 million round of financing

RaNA Therapeutics, Inc. today announced it has completed a $20.7 million round of financing co-led by Atlas Venture, SR One, and Monsanto, with participation of Partners Innovation Fund. The company is developing a technology platform to enable selective activation of target genes and expression of therapeutic factors by targeting a type of regulatory RNA called long non-coding RNA.

18 Jan 2012

Ivera receives new FDA clearance for Curos disinfecting port protector

Ivera Medical Corporation today announced it has received a new FDA 510(k) clearance for its Curos disinfecting port protector which reflects the company's ongoing determination to continuously improve its products to better deliver solutions designed to reduce hospital-acquired catheter related bloodstream infections.

18 Jan 2012

Study explains how cells regulate their bonds during new blood vessel development

New research explains how cells regulate their bonds during the development of new blood vessels. For the first time, the role of the protein Raf-1 in determining the strength of the bond between cells has been shown.

18 Jan 2012

Animal study confirms dramatic effects of natural formula against prostate cancer

New animal study confirms the dramatic effects of a natural formula against aggressive prostate cancer tumors. Researchers at the Methodist Research Institute at Indiana University conducted the study on mice, using a human prostate cancer xenograft model.

17 Jan 2012